Search results
Flu vs COVID: Stark Disparity in Vaccination and Deaths
Medscape· 15 hours agoIn the first half of 2023, COVID-19 killed 42,670 people in the United States, while the flu killed...
Study confirms effectiveness of bivalent COVID-19 vaccine
Medical Xpress· 7 days agoThis was the first research project conducted to evaluate the immunity induced by the Pfizer...
Moderna Quarterly Sales Beat Expectations but Plummet From Previous Year
US News & World Report· 10 hours agoSales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million...reaffirmed that it expects to ...
Earnings call: Pfizer raises 2024 EPS outlook despite revenue decline By Investing.com
Investing.com· 23 hours agoDespite a 19% decline in total company revenues to $14.9 billion, primarily due to the reduced...
Pfizer Inc (PFE) Q1 2024 Earnings Call Transcript Highlights: Navigating Post-COVID Challenges ...
GuruFocus.com via Yahoo Finance· 13 hours agoThe performance of IBRANCE and SULPERAZON was dampened by lower global demand, particularly in China. Pfizer Inc (NYSE:PFE) is navigating challenges in the post...Highlights ...
US opens COVID vaccine to little kids, shots begin next week
AOL· 3 days agoThe U.S. on Saturday opened COVID-19 vaccines to infants, toddlers and preschoolers. The shots will...
Pfizer’s first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Market Watch· 1 day agoAn expected drop in COVID-19-related product sales, including antiviral Paxlovid and vaccine...
Moderna posts quarterly sales beat, smaller loss than expected
Reuters via Yahoo Finance· 10 hours ago(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 6 hours ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna Puts Up Big Quarterly Beat; Could Shares Break Out?
Investor's Business Daily· 10 hours agoThe Covid vaccine maker came out of the March quarter with a $3.07 loss per share, reversing from a...